Elementis (LSE: ELM) has reshaped itself into a pure-play specialty chemicals group focused on Personal Care and Coatings. After a string of divestments, a repeated takeover target, and a self-help strategy, this FTSE 250 company presents a genuinely nuanced mix of margin progress, soft coatings demand and balance-sheet questions.
The Quick Version
- Elementis is built around hectorite clay rheology modifiers, now organised into two segments: Personal Care and Coatings.
- In full-year 2025 results, revenue was broadly flat at $597.5m while the adjusted operating margin rose to 21.2% and adjusted diluted EPS climbed 14.2% to 13.7 cents.
- The group has become a pure-play business after selling Chromium (2022-23) and Talc (May 2025), funding a $50m buyback, and agreeing to sell its pharmaceutical unit in early 2026.
- Elementis has attracted several takeover approaches since 2020, from Minerals Technologies, Innospec and KPS Capital Partners, and faced pressure from activist Franklin Mutual Advisers.
- Risks include soft coatings demand, net debt of $185.4m, commodity and FX exposure, and execution risk in medium-term margin targets.
What Elementis Actually Does
Founded in 1844, Elementis is built around hectorite, a rare natural clay it mines and refines into rheology modifiers — additives that control how liquids flow and thicken, sold under brands like Bentone. Following disposals, it reports through two segments: Personal Care (skincare, cosmetics, antiperspirants) and Coatings (paints, inks, industrial finishes). Personal Care accounts for roughly 38% of revenue but just over half of adjusted operating profit, reflecting its higher margins.
Why Elementis Keeps Attracting Takeover Interest
Since 2020, Elementis has fielded and rejected a succession of approaches. Minerals Technologies made an all-cash proposal in late 2020 (rejected, indicated around 130p/share). Innospec tabled 160p/share in 2021, valuing the company at roughly $1.3bn (rejected, then withdrawn). KPS Capital Partners reportedly proposed around 160p in December 2023 (also rejected). Activist shareholder Franklin Mutual Advisers, then holding around 9.8%, publicly urged the board to launch a sales process in September 2023 and again in January 2024, arguing the string of bids proved the company's desirability. The board has maintained its own strategy — simplifying the portfolio and improving margins under 'Elevate Elementis' — offers more value.
The Numbers: Margin Progress Despite Flat Revenue
In preliminary results for the year ended 31 December 2025, revenue was $597.5m, down about 1.0%, as Personal Care growth was offset by weaker Coatings volumes. Adjusted operating profit rose 4.6% at constant currency to $126.7m, lifting the adjusted operating margin by around 150 basis points to 21.2%. Adjusted diluted EPS grew 14.2% to 13.7 cents.
Statutory profit before tax was $89.9m, but the year recorded an overall statutory loss of around $45.5m — driven largely by the loss on disposal of the Talc business, not by trading. By segment, Personal Care grew revenue 3.3% to $224.5m (adjusted operating profit up 18.2% to $72.8m, margin 32.4%), while Coatings revenue fell 3.5% to $373.0m (adjusted operating profit down 10.2% to $70.4m, margin held at 18.9%). Net debt rose to $185.4m from $157.2m.
Growth Drivers
Management has set medium-term targets including an adjusted operating margin above 23%, cash conversion above 90% and ROCE excluding goodwill above 30% — if delivered, earnings could grow even in a subdued volume environment. Personal Care, the group's most profitable segment, could benefit from demand for natural and mineral-based ingredients, with the November 2025 Alchemy Ingredients acquisition (around $22m) expanding natural skincare capabilities. Having exited Chromium and Talc and agreed the pharmaceutical unit sale, Elementis has recycled capital toward a cleaner, higher-margin portfolio.
Dividend and Capital Allocation
Elementis lifted its full-year 2025 dividend by 7.5% to 4.3 cents per share. Because it's declared in US dollars, the sterling value received by UK shareholders varies with exchange rates, and the payout isn't guaranteed to grow every year. Following the Talc disposal in May 2025, the company launched a $50m share buyback, balancing this with modest bolt-on acquisitions and debt considerations — net debt of $185.4m at end-2025 constrains how aggressively the group can simultaneously return cash, invest and deleverage.
Why Valuation Needs Care Here
The statutory 2025 loss was distorted by the Talc disposal, so headline P/E measures based on statutory profit are misleading for the year — adjusted diluted EPS growth of 14.2% is the more meaningful metric. Shares have changed hands well below the levels implied by the 160p approaches of 2021 and 2023, part of why some shareholders have argued the stock is undervalued relative to its takeout appeal.
Risks Worth Weighing
Demand is the most visible near-term risk — Coatings revenue fell in 2025 amid a soft environment, and a prolonged downturn in construction or industrial activity could weigh further on volumes and margins. Balance-sheet and cash risks matter too: net debt rose to $185.4m and free cash flow declined year-on-year. Because Elementis reports in US dollars, sterling-based investors face currency translation risk on both earnings and dividends, and the medium-term margin, cash conversion and returns targets remain ambitions rather than guarantees.
What to Watch Next
Completion of the pharmaceutical business sale to Associated British Foods (agreed March 2026 for approximately €34m, expected to close Q2 2026). The 2026 interim results, which should show whether the margin improvement is being sustained and how Coatings demand is trending. Progress on the $50m buyback, movements in net debt, and any renewed corporate interest given the company's history.

_11_17_2026_13_00_51_895454.jpg)




Please wait processing your request...